These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3883743)

  • 21. Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption.
    Taylor RH; Jenkins DJ; Barker HM; Fielden H; Goff DV; Misiewicz JJ; Lee DA; Allen HB; MacDonald G; Wallrabe H
    Diabetes Care; 1982; 5(2):92-6. PubMed ID: 6927727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of starch malabsorption on colonic function and metabolism in humans.
    Scheppach W; Fabian C; Ahrens F; Spengler M; Kasper H
    Gastroenterology; 1988 Dec; 95(6):1549-55. PubMed ID: 3053313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.
    Uttenthal LO; Ukponmwan OO; Wood SM; Ghiglione M; Ghatei MA; Trayner IM; Bloom SR
    Diabet Med; 1986 Mar; 3(2):155-60. PubMed ID: 2951158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition.
    Hayakawa T; Kondo T; Okumura N; Nagai K; Shibata T; Kitagawa M
    Am J Gastroenterol; 1989 May; 84(5):523-6. PubMed ID: 2655436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of graded alpha-glucosidase inhibition on sugar absorption in vivo.
    Madariaga H; Lee PC; Heitlinger LA; Lebenthal E
    Dig Dis Sci; 1988 Aug; 33(8):1020-4. PubMed ID: 3292164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis.
    Zillikens MC; Swart GR; van den Berg JW; Wilson JH
    Aliment Pharmacol Ther; 1989 Oct; 3(5):453-9. PubMed ID: 2518858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Nutritive effects of an intestinal alpha-glucosidases-inhibition in rats (author's transl)].
    Kirchgessner M; Roth FX; Spoerl R
    Res Exp Med (Berl); 1981; 178(3):211-7. PubMed ID: 7015437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment in diabetics with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect on GI hormones.
    Hillebrand I; Aubell R; Boehme K; Bloom SR; Berchtold P
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():683-6. PubMed ID: 6393444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
    Krause HP; Keup U; Thomas G; Puls W
    Metabolism; 1982 Jul; 31(7):710-4. PubMed ID: 7045575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
    Madar Z
    J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alpha-Glucosidase inhibition in obesity.
    William-Olsson T
    Acta Med Scand Suppl; 1985; 706():1-39. PubMed ID: 3914827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbohydrate malabsorption following acarbose administration.
    Sobajima H; Mori M; Niwa T; Muramatsu M; Sugimoto Y; Kato K; Naruse S; Kondo T; Hayakawa T
    Diabet Med; 1998 May; 15(5):393-7. PubMed ID: 9609361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of alpha-glucosidase inhibition on intestinal disaccharidase activity in normal and diabetic mice.
    Lee SM; Bustamante SA; Koldovský O
    Metabolism; 1983 Aug; 32(8):793-9. PubMed ID: 6346004
    [No Abstract]   [Full Text] [Related]  

  • 34. New horizons in diabetes therapy--alpha glucosidase inhibitors.
    Jawad F
    J Pak Med Assoc; 1994 Mar; 44(3):59-60. PubMed ID: 8040998
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man.
    Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W
    Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition.
    McCulloch DK; Kurtz AB; Tattersall RB
    Diabetes Care; 1983; 6(5):483-7. PubMed ID: 6400709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor.
    Füessl HS; Adrian TE; Uttenthal LO; Bloom SR
    Klin Wochenschr; 1988 Oct; 66(19):985-9. PubMed ID: 3054280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of inhibition of intestinal glucosidase on protein and energy balance in rats].
    Kirchgessner M; Spoerl R; Roth FX
    Ann Nutr Metab; 1981; 25(3):194-200. PubMed ID: 7025747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers.
    Holt PR; Thea D; Yang MY; Kotler DP
    Metabolism; 1988 Dec; 37(12):1163-70. PubMed ID: 3057329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of beano on the tolerability and pharmacodynamics of acarbose.
    Lettieri JT; Dain B
    Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.